Infertile women were eligible for this trial if they were scheduled to their first IVF.All patients were younger than 40 years, having regular cycles (28–32 days per cycle), having a normal uterine cavity as attested by normal systematic TVUS transvaginal ultrasound and HSG (absence of intra-uterine pathologies such as polyps, fibroids or septa), having FSH level less than 10 UI/l and an antral follicular count ≥12. All patients had a BMI ranged from 19 to 30 Kg/m2 and had given their oral consent after being clearly informed. The gene discussed is BRD2; the disease is leiomyoma.